ASCO GU 2021 Prostate Cancer VL

Genomics Guide Treatment Decisions in Post Prostatectomy Patients - Ashley Ross

Details
A recent systematic review assessed the clinical utility of the Decipher® genomic classifier. This genomic classifier assesses 22 genes representing multiple oncologic pathways and is independently prognostic of oncologic outcomes. During the 2021 ASCO GU Cancers Symposium, Ashley Ross, MD, PhD, highlighted this review and presented on the use of genomics to guide treatment decisions in post-prost...

Radium-223 plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer - Benjamin Maughan

Details
Benjamin Maughan, MD joins Charles Ryan, MD in a discussion on investigational therapy currently being testing of a combination of enzalutamide and radium-223 compared to enzalutamide alone, both FDA-approved therapies for metastatic castration-resistant prostate cancer (mCRPC). This was a randomized study, patients were randomized to standard of care and enzalutamide or six cycles of radium plus...

Evaluating Circulating Tumor Cells in Patients on the CARD Trial - Eleni Efstathiou

Details
In the PHASE 4 CARD trial, cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer who had received docetaxel and progressed within 12 months with the alternative androgen-signaling-targeted inhibitor. In this conversation, Alicia Morgans, MD, MPH, and E...

Practice Patterns of Metastatic Castration-Sensitive Prostate Cancer in the Veterans Healthcare Administration - Stephen Freedland & Scott Tagawa

Details
In this conversation with Alicia Morgans, MD, MPH, Drs Scott Tagawa and Stephen Freedland highlight real-world evidence of survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Veterans Health Administration system. Drs. Tagawa, Freedland, and colleagues used the Veterans Health Administration claims data to identify patients with mCSPC who initiated ADT...

Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad

Details
Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced pr...

Biological Signatures of Patients with Long-Term Responses to Apalutamide and Placebo in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)- Felix Feng

Details
Alicia Morgans is joined by Felix Feng to discuss molecular determinants associated with response to apalutamide in patients who have nonmetastatic castration-resistant prostate cancer (nmCRPC). SPARTAN, a phase 3 placebo-controlled study in patients (pts) with nmCRPC, showed that apalutamide plus androgen deprivation therapy (ADT) significantly improves metastasis-free survival compared with plac...

The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish Choudhury

Details
Joining Alicia Morgans to discuss a plenary abstract presentation from the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) is Atish D. Choudhury, MD, Ph.D. Dr. Choudhury and colleagues presented the results of a phase II study to assess the safety of the combination and differences in immune cell infiltrate in bone biopsies (bx) and preliminary clinical activit...

Biomarker Analysis from a Randomized Study of Olaparib With or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)- Rana Mckay

Details
The field of advanced prostate cancer has rapidly progressed. Prior to the publication of TAX-327, in 2004 there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen axis, and bone-target...

Phase I RAMP Study Evaluating the Combination of Enzalutamide and Rucaparib in mCRPC - Arpit Rao

Details
Arpit Rao joins Alicia Morgans to discuss the Phase I RAMP trial, looking at the combination of enzalutamide and rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Preclinical studies have demonstrated potential synthetic lethality between androgen receptor signaling inhibition and PARP inhibition, which led to the investigation of these two drugs in combination. The RAMP study...

PSMA-Directed CAR-T First-in-Human Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Vivek Narayan

Details
Joining Alicia Morgans to discuss the first-in-human phase 1 clinical trial to evaluate the feasibility, safety and preliminary efficacy of PSMA-directed/TGFβ-insensitive CAR-T cells (CAR-T-PSMA-TGFβRdn) in patients with metastatic castration-resistant prostate cancer (mCRPC) is Vivek Narayan, MD, MS. Dr. Narayan presented this novel evolving therapeutic approach to mCRPC at the 2021 ASCO GU sympo...
email news signup